Overview

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Status:
RECRUITING
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
Phase:
PHASE2
Details
Lead Sponsor:
Neurocentria, Inc.